Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide drug candidate, as part of an ongoing licensing deal with US-based RayzeBio. The agreement aims to develop and commercialize the product in Greater China, expanding Ablaze’s portfolio and strengthening its commitment to cancer therapies.
Licensing Deal and Partnership with RayzeBio
Under the existing agreement, Ablaze Pharma is in the process of securing a licensing deal with RayzeBio, which will grant them development and commercialization rights for the GPC3-targeted product in the region. This partnership builds on an already established relationship between Ablaze and RayzeBio, through which Ablaze has obtained rights to several other assets in RayzeBio’s portfolio.
GPC3 as a Biomarker and RayzeBio’s Drug Candidate
GPC3 is a significant biomarker for diagnostic imaging and targeted therapy, uniquely expressed in hepatocellular carcinoma and not present in normal or other pathological liver tissues. RayzeBio’s candidate drug has shown promising results in preclinical models, demonstrating effective selective binding to GPC3, rapid intracellular internalization, and sustained tumor-specific uptake, along with significant antitumor efficacy.
Ablaze Pharma and RayzeBio: A Focus on Cancer Therapeutics
Founded in 2021, Ablaze Pharma is a clinical-stage company dedicated to developing therapies for the benefit of cancer patients in China. RayzeBio, established in 2020, is focused on developing conjugates that target solid tumors to provide therapeutic radioisotopes, offering innovative treatment options for cancer patients.-Fineline Info & Tech
